Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front

Abstract

Protein arrays are described for screening of molecular markers and pathway targets in patient matched human tissue during disease progression. In contrast to previous protein arrays that immobilize the probe, our reverse phase protein array immobilizes the whole repertoire of patient proteins that represent the state of individual tissue cell populations undergoing disease transitions. A high degree of sensitivity, precision and linearity was achieved, making it possible to quantify the phosphorylated status of signal proteins in human tissue cell subpopulations. Using this novel protein microarray we have longitudinally analysed the state of pro-survival checkpoint proteins at the microscopic transition stage from patient matched histologically normal prostate epithelium to prostate intraepithelial neoplasia (PIN) and then to invasive prostate cancer. Cancer progression was associated with increased phosphorylation of Akt (P<0.04), suppression of apoptosis pathways (P<0.03), as well as decreased phosphorylation of ERK (P<0.01). At the transition from histologically normal epithelium to PIN we observed a statistically significant surge in phosphorylated Akt (P<0.03) and a concomitant suppression of downstream apoptosis pathways which proceeds the transition into invasive carcinoma.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Arenkov P, Kukhtin A, Gemmell A, Voloshchuk S, Chupeeva V, Mirzabekov A . 2000 Anal. Biochem. 278: 123–131

  • Bostwick DG . 1995 Cancer 75: 1823–1836

  • Buckholtz RG, Simmons CA, Stuart JM, Weiner MP . 1999 J. Mol. Microbiol. Biotechnol. 1: 135–140

  • Cross DAE, Alessi DR, Cohen P, Adndjelkovich M, Hedmmings BA . 1995 Nature 378: 785–788

  • DeRisi J, Penland L, Brown PO, Bittner ML, Meltzer PS, Ray M, Chen Y, Su YA, Trent JM . 1996 Nat. Genet. 4: 457–460

  • Dimmeler S, Zeiher AM . 2000 Circ. Res. 86: 4–5

  • Ekins RP, Chu FW . 1991 Clin. Chem. 37: 1955–1967

  • Emili AQ, Cagney G . 2000 Nat. Biotechnol. 18: 393–397

  • Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein S, Liotta LA . 1996 Science 274: 1481–1483

  • Emmert-Buck MR, Gillespie JW, Paweletz CP, Ornstein DK, Basrur V, Appella E, Wang QH, Huang J, Hu N, Taylor P, Petricoin III EF . 2000 Mol. Carcinog. 27: 158–165

  • Englert CR, Baibakov GV, Emmert-Buck MR . 1999 Cancer Res. 60: 1526–1530

  • Fodor SPA, Read JL, Pirrung MC, Stryer L, Lu AT, Solas D . 1991 Science 251: 767–773

  • Franke TF, Kaplan DR, Cantley LC . 1997 Cell 88: 435–437

  • Frey RS, Mulder KM . 1997 Cancer Res. 57: 628–633

  • Ge H . 2000 Nucleic Acid Res. 28: e3

  • Gioeli D, Mandell JW, Petroni GR, Frierson Jr HF, Weber MJ . 1999 Cancer Res. 59: 279–284

  • Graff JR, Konicek BW, McNulty AM, Wang ZJ, Houck K, Allen S, Paul JD, Hbaiu A, Goode RG, Sandusky GE, Vessella RL, Neubauer BL . 2000 JBC. 275: 24500–24505

  • Haab BB, Dunham JM, Brown PO . 2001 Genome Biology 2: 1–13

  • Hanahan D, Weinberg RA . 2000 Cell 100: 57–70

  • Jones WV, Kenseth JR, Porter MD, Mosher CL, Henderson E . 1998 Anal. Chem. 70: 1233–1241

  • Koch M, Miguel M, de Hoefler H, Diaz-Cano SJ . 2000 Virchows Arch. 436: 413–420

  • Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP . 1998 Nat. Med. 4: 844–847

  • Krajewaska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S, Reed JC . 1996 Am. J. Pathol. 1148: 1567–1576

  • Lipshutz RJ, Fodor SP, Gingeras TR, Lockhart DJ . 1999 Nat. Genet. 1: suppl 20–24

  • Lueking A, Horn M, Eickhoff H, Büssow K, Lehrach H, Walter G . 1999 Anal. Biochem. 270: 103–111

  • MacBeath G, Koehler AN, Schreiber SL . 1999 JACS 121: 7966–7968

  • Marshall CJ . 1995 Cell 80: 179–185

  • Ornstein DK, Gillespie JW, Paweletz CP, Duray PH, Herring J, Vocke CD, Topalian SZ, Bostwick DG, Linehan WM, Petricoin III EF, Emmert-Buck MR . 2000 Electrophoresis 21: 2235–2242

  • Page MJ, Amess B, Townsend RR, Parekh R, Herath A, Brusten L, Zvelebil MJ, Stein RC, Waterfield MD, Davies SC, O'Hare MJ . 2000 PNAS 96: 12589–12594

  • Pap M, Cooper GM . 1998 JBC 273: 19929–19932

  • Paweletz CP, Ornstein DK, Roth MJ, Bichsel VE, Gillespie JW, Calvert VS, Vocke CD, Hewitt SM, Duray PH, Herring J, Wang QH, Hu N, Lineham WM, Taylor PR, Liotta LA, Emmert-Buck MR, Petricoin EF . 2000 Cancer Res. 60: 6293–6297

  • Rowe AC, Tender LM, Feldstein MJ, Golden JP, Scruggs SB, MacCraith BD, Cras JJ, Ligler FS . 1999 Anal. Chem. 71: 3846–3852

  • Schena M, Shalon D, Davis RW, Brown PO . 1995 Science 270: 467–470

  • Williams KL, Hochstrasser DF . 1997 Proteome Research: New Frontiers in Functional Genomics. Wilkins MR, Williams KL, Appel RD and Hochstrasser DF (eds) Springer: Berlin, Germany 1–11

  • Xie W, Wong YC, Tsao SW . 2000 Prostate 44: 31–39

  • Yao R, Cooper G . 1995 Science 267: 2003–2006

  • York RD, Yao H, Dillon T, Ellig CL, Eckert SP, McClesky EW, Stork PJS . 1998 Nature 392: 622–626

  • Zheng DQ, Woodward AS, Tallini G, Languino LR . 2000 JBC 275: 24565–24574

  • Zimmermann S, Moelling K . 1999 Science 286: 1741–1744

Download references

Acknowledgements

We thank Dr Phil R Taylor of the Cancer Prevention Studies Branch, National Cancer Institute, Bethesda, Maryland, USA, and Drs Quan-Hong Wang, Wen-Jie Guo and Yong-Zhen Zhang of the Shanxi Cancer Hospital and Institute, Taiyuan, Shanxi, China for coordinating and conducting all the field related and tissue procurement activities in China.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Paweletz, C., Charboneau, L., Bichsel, V. et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20, 1981–1989 (2001). https://doi.org/10.1038/sj.onc.1204265

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204265

Keywords

This article is cited by

Search

Quick links